Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Navidea Biopharmaceuticals, Inc.

< Previous 1 2 Next >
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces New Senior Regulatory Consultant and Return of Former Director of Regulatory Affairs
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals to Host Fourth Quarter 2021 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.